A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

NCT02614560 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Fludarabine
DRUG: Melphalan
DRUG: vadastuximab talirine
DRUG: vadastuximab talirine

Sponsor

Seagen Inc.